Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Among the company's investments to "transform" its specialty pharmacy services is the opening of a new facility dedicated to cell and gene therapy services.

Walgreens to help bring cell and gene therapies to patients as it expands specialty pharmacy services

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens is expanding its specialty pharmacy services and investing in its capabilities as the company further grows its core pharmacy business to improve patient outcomes and provide greater value to payers and partners. The company today introduced Walgreens Specialty Pharmacy, a holistic offering that expands access to care for patients with complex, chronic conditions and enables partnerships that drive profitability for Walgreens' pharmacy business. The c.

Walgreens Launches Gene and Cell Services as Part of Newly Integrated Walgreens Specialty Pharmacy Business

DoorDash

SAN FRANCISCO--(BUSINESS WIRE)--DoorDash (NASDAQ: DASH), the local commerce platform, and Walgreens (NASDAQ: WBA), a trusted, neighborhood health destination serving nearly 10 million customers each day, today announced a new collaboration to offer SNAP/EBT payment at nearly 7,800 Walgreens stores across the country. DoorDash is the first platform that enables SNAP customers to make purchases directly from Walgreens using their SNAP/EBT cards. In addition, DoorDash is the first third-party deli.

DoorDash and Walgreens Launch Unprecedented Access for SNAP Customers

British American Tobacco

Johnson & Johnson

Altria

Pfizer

AT&T

Verizon

In the changing environment of 2024, astute investors have a plethora of options to strengthen their financial portfolios strategically by purchasing dividend stocks. These prospects result from industry titans' forward-thinking initiatives and solid performance.

The Top 7 Dividend Stocks to Buy in 2024 to Build Lasting Wealth

Expeditors International of Washington

Illinois Tool Works

The rubber hit the road on April 15 as Tesla (NASDAQ: TSLA ) announced it was cutting more than 10% of its global headcount to reduce costs and increase productivity. “As we prepare the company for our next phase of growth, it is extremely important to look at every aspect of the company for cost reductions and increasing productivity,” Investor's Business Daily reported Elon Musk's comments from his memo sent to employees.

Layoffs 2024: 3 Stocks That Ought to Copy Tesla's Job Cuts

Best Buy

Simon Property Group

Take the quiz below to get matched with a financial advisor today. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

6 Left For Dead Blue Chip Dividend Stocks Could Rally Big This Summer

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens is calling on the public to help in the fight against prescription drug abuse by taking part in National Prescription Drug Take Back Day on Saturday, April 27th, 2024. Drug take back days are reserved annually for the safe disposal of unwanted, unused, or expired medications. Walgreens has more than 1,550 kiosks across 46 states and Washington, D.C. These kiosks are a convenient way to ensure medications are not accidentally or intentionally misused.

Walgreens Encourages Safe Drug Disposal on National Drug Take Back Day Saturday April 27

Walgreens (NASDAQ: WBA ) layoffs are a hot topic on Thursday after the pharmacy company announced plans to cut jobs! The latest statement notes that Walgreens isn't revealing the number of employees who are being cut in these layoffs.

Walgreens Layoffs 2024: What to Know About the Latest WBA Job Cuts

Intel

Philip Morris

PayPal

Warner Bros Discovery Inc

Seven stocks stand out due to their strategic placement and excellent growth prospects among many investing alternatives. With careful post-merger integration, the first one has improved operating efficiency and produced significant savings, setting it up for future success.

The Underpriced Steals: 7 Stocks You Can't Afford to Overlook This Year

Dow Inc

Want retirement to come a few years earlier than you'd planned? Or are you ready to retire now, but want an extra set of eyes on your finances?

The 4 Dogs of the Dow With the Biggest Dividend Payouts Can Rule

Alibaba

JD.com

If you're on the hunt for overlooked stocks to buy, look no further. Below is a carefully chosen list of seven underappreciated treasures, all full of unrealized potential and ready to cause a stir on Wall Street.

Underestimated Giants: 7 Stocks Set to Take Wall Street by Storm

iRobot

Walgreens Boots Alliance has a new CEO who isn't afraid of making tough decisions. iRobot is slashing costs to improve its financials after its deal with Amazon fell through.

2 Beaten-Down Stocks That Haven't Been This Cheap in More Than 10 Years

Amazon

Walgreens has invested billions into primary care in recent years. The company is offering in-person assistance and guidance to patients.

This Is How Walgreens' New CEO Thinks the Company Can Beat Amazon

Carnival

Opendoor

Royal Caribbean Cruises

Sabre

In February, JPMorgan Chase (NYSE: JPM ) CEO Jamie Dimon unloaded $150 million of his company's stock – his first-ever sale. Shares of the bank had risen 70% since 2022, and valuations were beginning to look rich.

5 Stocks to Buy as Interest Rates Begin to Fall

Walgreens cut its dividend this year. The company's latest earnings numbers weren't great because even without impairment charges, Walgreens would still have reported a loss.

Is Walgreens Boots Alliance's Dividend Still Safe?

Amcor Plc

Air Products and Chemicals

Franklin Resources

Chevron

Essex Property Trust

Fastenal

Federal Realty Investment Trust

Hormel Foods

Kimberly-Clark

Kenvue

Medtronic

NextEra Energy

Realty Income Corp

J. M. Smucker

T. Rowe Price Group

V.F.

"Dividend Aristocrats. in the S&P 500 Index… have raised their annual payouts every year for at least 25 consecutive years. "-- Kiplinger.com/Investing.

4 Dividend Aristocrats Signal Buy In April Plus 6 To Watch

Dollar Tree

Lululemon Athletica

Snowflake

Synopsys

Many investors closely monitor insider buys, as they can provide meaningful insight into the longer-term picture of a company. And recently, they've been deploying cash for these five stocks.

Insiders Are Buying These 5 Stocks

Walgreens is a 2,500lb great white in the global healthcare system, but the stock is a minnow. The U.S. Pharmacy business is structurally broken, but the reimbursement model is set for a major change and Walgreens hired the right man for the job. The most recent quarter suggests that business trends remain strong despite a soft global consumer environment.

Walgreens: New Management Team And Cost-Plus Model Are Exactly What The Doctor Prescribed

To hit that price, the shares would have to rise by nearly 90%. The analyst feels the pharmacy chain operator is extremely undervalued.

Is Walgreens Boots Alliance Stock Going to $35? 1 Wall Street Analyst Thinks So.

Gigacloud Tech

Vital Energy Inc

Momentum has been driving the market, led by artificial intelligence stocks, with the S&P 500 up 10% for the first quarter. However, the markets have started broadening, with financials, industrials and energy stocks also rallying.

The 3 Best Bargain Stocks to Buy in April 2024

Walgreens stock trades for less than 6 times forward earnings. The company recently narrowed its outlook for the year, and TD Cowen sees these targets as achievable.

Walgreens Boots Alliance Stock Has 87% Upside, According to 1 Wall Street Analyst

CVS Health

Zacks Retail-Pharmacies and Drug Stores industry players like CVS and WBA are likely to gain despite reimbursement challenges that are hurting the overall health industry. HLF might face the wrath of economic challenges.

2 Retail Pharmacy Stocks to Watch and One to Avoid Amid Industry Headwinds

Walgreens recently reported its Q2'24 results (fiscal ends in August), with revenue and earnings exceeding the street expectations. The company reported revenue of $37.1 billion and adjusted earnings of $1.20 per share, compared to the consensus estimates of $35.9 billion, and $0.82, respectively.

Should You Pick Walgreens Stock At $20?

As Walgreens Boots Alliance chief executive Tim Wentworth works to engineer a financial turnaround of the iconic drugstore chain, he and his executive team are working with state and federal regulators to expand the role of the pharmacist to provide more healthcare services.

News for Walgreens Stock (WBA)